18:11 , Jul 27, 2018 |  BC Week In Review  |  Financial News

With Ex-Receptos execs at helm, Gossamer raises another large round

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million on July 23 in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January...
20:56 , Jul 26, 2018 |  BioCentury  |  Finance

Gossamer’s war chest

Gossamer Bio Inc. has built a huge war chest from investors lured by the prospect of near-term milestones, a plan for rapid pipeline growth and a winning management team from Receptos Inc. With Monday’s $230...
20:21 , Jul 23, 2018 |  BC Extra  |  Financial News

Ex-Receptos team snags another big round at Gossamer

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January launch. Also participating...
19:50 , Apr 20, 2018 |  BC Week In Review  |  Company News

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
23:47 , Apr 16, 2018 |  BC Extra  |  Tools & Techniques

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
12:32 , Feb 27, 2018 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...
00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Bleeding Patient sample and mouse studies suggest HIF1A stabilizers could help treat heavy menstrual bleeding. In endometrial samples from patients, levels of HIF1A were lower than in patients with normal menstrual bleeding. In a mouse...
00:24 , Jan 24, 2018 |  BC Extra  |  Preclinical News

HIF inhibition could prevent chemo-induced TNBC tumor recurrence

A study published in Proceedings of the National Academy of Sciences suggests combining hypoxia-inducible factor (HIF) inhibitors with chemotherapy could help prevent recurrence of triple-negative breast cancer (TNBC). In the paper, researchers from Johns Hopkins...
18:36 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Patient sample and mouse studies suggest inhibiting HIF1A could help treat acute lung injury (ALI). Levels of HIF1A in lung tissue samples from patients with idiopathic pulmonary fibrosis (IPF) and a mouse...